Aktie 693609 ESSEX BIO-TECHNOLOGY LIMITED
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Essex Bio-Technology Limited

Aktien

693609

KYG312371035

1061

Markt geschlossen - Hong Kong S.E.
Andere Börsenplätze
 10:08:17 07.05.2024 		% 5 Tage % 1. Jan.
2,48 HKD -0,80 % Intraday Chart für Essex Bio-Technology Limited +7,83 % -0,40 %
19.03. Gewinn von Essex Bio-Technology steigt 2023 dank höherer Umsätze um 22% MT
18.03. Essex Bio-Technology Limited schlägt letzte ordentliche Dividende für das am 31. Dezember 2023 endende Geschäftsjahr vor, zahlbar am 17. Juni 2024 CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong
Essex Bio-Technology Limited(SEHK:1061) dropped from S&P Global BMI Index
Essex Bio-Technology's Profit Jumps 22% in H1
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration
Essex Bio-Technology Limited Announces Early Repayment of Loan Facility
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.
Essex Bio-Technology Limited Announces Director Changes
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022
Essex Bio-Technology Limited's Equity Buyback announced on May 12, 2022 has expired.
Essex and Osteopore Entered into Exclusive Distribution Agreement
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 693609 Aktie
  4. Nachrichten Essex Bio-Technology Limited
  5. Andere Sprachen